More From the CardioNerds
The CardioNerds and colleagues review the differential diagnosis for peripartum cardiomyopathy. A study shows how how advancements in diagnostic tools and treatments for ATTR-CM have improved risk profiles. A recent post-hoc analysis of the ATTRibute-CM trial shows the potential for acoramidis in treating ATTR-CM. The CardioNerds discuss a case involving a patient who presented with stress cardiomyopathy leading to cardiogenic shock. A study highlights the significant HCRU and costs associated with ATTR-CM. Promising long-term outcomes from the ongoing OLE of the ATTRibute-CM trial highlight the efficacy of acoramidis.